Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Slides:



Advertisements
Similar presentations
Metastatic Gastric Cancer
Advertisements

DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)
Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Morganstein (Prof Van Cutsem) 78 yo woman with Stage IV GE adenocarcinoma.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
ESMO/ECCO Presidential Session III
Discussion abstracts Alberto Sobrero MD Ospedale San Martino Genoa, Italy.
Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Schwartz 44 yo woman with 4 mo hx of abdominal pain –Imaging = pancreatic.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
Poster #382 XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.
Quality of life results from a Phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer Taroh.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Baselga J et al. Proc SABCS 2010;Abstract S3-3.
Tolerability of fluoropyrimidines differs by region Daniel G. Haller on behalf of: Cassidy J, Clarke S, Cunningham D, Van Cutsem E Hoff P, Rothenberg M,
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.
Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR TREATMENT OF HER2- POSITIVE ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Case presented by Dr Polkinghorn
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Gajria D et al. Proc SABCS 2010;Abstract P
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
Blackwell KL et al. SABCS 2009;Abstract 61
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage
Case presented by Dr Schwartz
Swain SM et al. Proc SABCS 2012;Abstract P
National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.
Case presented by Dr Moriarty
National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.
Krop I et al. SABCS 2009;Abstract 5090.
Oesophageal and Gastric cancer: neo-adjuvant therapy
Jordan Berlin Co-Director, GI Oncology Program
Adjuvant Radiation is Required for Gastric Cancer
National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.
Adjuvant Therapy in Gastric Cancer: Radiation Therapy Adds Nothing!
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
1 Sunnybrook Odette Cancer Centre, University of Toronto, Canada
1Cancer Research UK, Glasgow, United Kingdom
1Sunnybrook Health Sciences Centre, University of Toronto, Canada
Presentation transcript:

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00 PM – 9:30 PM San Francisco, California Moderator Neil Love, MD Eileen M O’Reilly, MD Eric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD Charles D Blanke, MD David Cunningham, MD Steven A Curley, MD

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Morganstein 67 yo man: PMH – Barrett’s/GERD and CAD, but EF good at 70% 8/2008: Stage III (T2N3) GE adenocarcinoma  neoadjuvant cisplatin/irinotecan + XRT  resection Late 2009: Lung mets confirmed on biopsy –HER2-positive (amplified = 4.0) –FOLFOX + trastuzumab, but poor tolerance to oxali  5-FU/LV + trastuzumab = response –Seen by cardiologist while on tx  EF  30% (global hypokinesis)  D/C all treatment –Follow up ECHO  still low EF

Copyright © 2011 Research To Practice. All rights reserved.

Case presented by Dr Morganstein 67 yo man: PMH – Barrett’s/GERD and CAD, but EF good at 70% 8/2008: Stage III (T2N3) GE adenocarcinoma  neoadjuvant cisplatin/irinotecan + XRT  resection Late 2009: Lung mets confirmed on biopsy –HER2-positive (amplified = 4.0) –FOLFOX + trastuzumab, but poor tolerance to oxali  5-FU/LV + trastuzumab = response –Seen by cardiologist while on tx  EF  30% (global hypokinesis)  D/C all treatment –Follow up ECHO  still low EF

Copyright © 2011 Research To Practice. All rights reserved.

Case presented by Dr Morganstein 67 yo man: PMH – Barrett’s/GERD and CAD, but EF good at 70% 8/2008: Stage III (T2N3) GE adenocarcinoma  neoadjuvant cisplatin/irinotecan + XRT  resection Late 2009: Lung mets confirmed on biopsy –HER2-positive (amplified = 4.0) –FOLFOX + trastuzumab, but poor tolerance to oxali  5-FU/LV + trastuzumab = response –Seen by cardiologist while on tx  EF  30% (global hypokinesis)  D/C all treatment –Follow up ECHO  still low EF

Copyright © 2011 Research To Practice. All rights reserved. Bang YJ et al. Lancet 2010;376(9742): Cardiac Safety of Trastuzumab + Chemotherapy versus Chemotherapy Alone in HER2-Positive Advanced Gastric or GE Junction Tumors Chemo Alone (n = 290) Chemo + T (n = 294) Cardiac Adverse Events (AEs) (All Grades) 6% Cardiac AEs (Grade 3/4) 3%1% Cardiac Failure<1% Cardiac Dysfunction (≥10% drop in LVEF to an absolute value <50%)* 1%5% * n = 187 for Chemo alone arm, n = 237 for Chemo + T arm

Copyright © 2011 Research To Practice. All rights reserved. Ongoing Phase II/III Trials: HER2-Positive Gastric Cancer Study Phase Target Accrual DesignStudy Endpoints Metastatic Gastric Cancer LOGiCIII 535 (open) CapeOx + lapatinib or placebo OS PFS ORR EORTC-40071II 192 (open) ECF/X +/- lapatinib OS PFS ORR NCT II 36 (open) CapeOx + bevacizumab + trastuzumab ORR Operable Gastric Cancer NCT II45 XELOX + trastuzumab DFS January 2011.

Copyright © 2011 Research To Practice. All rights reserved. Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro- Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial Bang YJ et al. Lancet 2010;376(9742):

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Morganstein 67 yo man: PMH – Barrett’s/GERD and CAD, but EF good at 70% 8/2008: Stage III (T2N3) GE adenocarcinoma  neoadjuvant cisplatin/irinotecan + XRT  resection Late 2009: Lung mets confirmed on biopsy –HER2-positive (amplified = 4.0) –FOLFOX + trastuzumab, but poor tolerance to oxali  5-FU/LV + trastuzumab = response –Seen by cardiologist while on tx  EF  30% (global hypokinesis)  D/C all treatment –Follow up ECHO  still low EF